Home ›
Diffuse Large B-Cell (DLBCL) Lymphoma Trials ›
NCT07189065
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with non-GCB DLBCL.
Trial Details
NCT ID NCT07189065
Phase PHASE2
Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Status RECRUITING
Cancer Type Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions Rocbrutinib Bendamustine Rituximab Lenalidomide
Locations (sample) Hefei, Anhui, China|31.86389,117.28083 Beijing, Beijing Municipality, China|39.9075,116.39723 Beijing, Beijing Municipality, China|39.9075,116.39723 Beijing, Beijing Municipality, China|39.9075,116.39723 Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
Age ≥18 years, any gender. Pathologically confirmed DLBCL (not otherwise specified) according to the revised 2017 WHO classification of lymphoid neoplasms, with non-germinal … Patients who are refractory or have relapsed after at least two prior lines of therapy (at least one line must include an anti-CD20 antibody-contai… At least one measurable lesion (nodal lesion with longest diameter \>1.5 cm, extranodal lesion with longest diameter \>1.0 cm).
For full eligibility, visit ClinicalTrials.gov .